Failure of buspirone and verapamil to improve spasmodic torticollis.
The effects of buspirone and verapamil on spasmodic torticollis were investigated in two double-blind, placebo-controlled crossover studies. Buspirone was given in doses of 20-100 mg/day for 4 weeks to 14 patients; verapamil was given in doses of 40-100 mg/day for 3 weeks to 8 patients. Neither drug improved symptoms of the movement disorder (posture, motility, rigidity, tremor), pain, perceived stress, or mood, either in the whole group or in any individual patient.
Naber
D
D
Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, Maryland.
Weinberger
D R
DR
Gillespie
M
M
Chase
T N
TN
D000328:Adult; D002065:Buspirone / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009460:Neurologic Examination / Q000187:drug effects; D014103:Torticollis / Q000188:drug therapy*; D014700:Verapamil / Q000627:therapeutic use*
D014700:Verapamil; D002065:Buspirone